Ambrx Biopharma Inc.
Ambrx Biopharma Inc. (AMAM) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
amam · stock forecast · 6 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 6 Wall Street analysts in the past 3 months
Hold
6 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $28.00
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $28.00 | ↑ 0.01% |
1-day model range: $27.99–$28.01. Peak: $28.01 (+0.01%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
NEUTRAL
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · AMAM · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-01-16 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2024-01-10 | JMP Securities | Downgrade ↓ | Market Outperform→Market Perform |
| 2024-01-09 | B. Riley Securities | Downgrade ↓ | Buy→Neutral |
| 2023-11-29 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-11-20 | JMP Securities | Maintains | Market Outperform→Market Outperform |
| 2023-11-15 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2023-11-14 | RBC Capital | Maintains | Outperform→Outperform |
| 2023-10-23 | RBC Capital | Maintains | Outperform→Outperform |
| 2023-10-23 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2023-09-18 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
Wall Street analysts have recently issued updated ratings on Ambrx Biopharma Inc. (AMAM) stock. Of the recent 22 rating actions, 0 were upgrades and 3 were downgrades. 6 analysts currently cover AMAM.
Analyst Recommendation Trends
AMAM analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$4M
↓ 3.6% YoY
Revenue Next Year
$6M
↑ 40.9% YoY
EPS This Year
$0.07
EPS Next Year
$-0.19
↓ 373.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast AMAM EPS of $0.07 for the current fiscal year, based on estimates from 1 analysts. The AMAM revenue forecast is $4M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The AMAM stock forecast is supported by two independent data sources: analyst consensus ratings from 6 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus AMAM price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The AMAM short-term stock prediction for tomorrow is $28.00 (+0.01%).
Ambrx Biopharma Inc. trades on NYSE under the ticker AMAM. The AMAM stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
AMAM forecast · 8 questionsAccording to 6 Wall Street analysts, the average 12-month AMAM price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $28.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.